The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis

Gwyneth Kong,Grace Cao,Jaycie Koh,Siew Pang Chan,Audrey Zhang,Esther Wong,Bryan Chong,Silingga Metta Jauhari,Jiong‐Wei Wang,Anurag Mehta,Gemma A. Figtree,Mamas A. Mamas,Gavin Ng,Koo Hui Chan,Ping Chai,Adrian F. Low,Chi Hang Lee,Tiong Cheng Yeo,James Yip,Roger Foo,Huay Cheem Tan,Daniel Q. Huang,Mark Muthiah,Mark Yan‐Yee Chan,Poay‐Huan Loh,Nicholas W. S. Chew
DOI: https://doi.org/10.1111/dom.15660
2024-05-25
Diabetes Obesity and Metabolism
Abstract:Aim Patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) are at increased risk of incident cardiovascular disease. However, the clinical characteristics and prognostic importance of MASLD in patients presenting with acute myocardial infarction (AMI) have yet to be examined. Methods This study compared the characteristics and outcomes of patients with and without MASLD presenting with AMI at a tertiary centre in Singapore. MASLD was defined as hepatic steatosis, with at least one of five metabolic criteria. Hepatic steatosis was determined using the Hepatic Steatosis Index. Propensity score matching was performed to adjust for age and sex. The Kaplan‐Meier curve was constructed for long‐term all‐cause mortality. Cox regression analysis was used to investigate independent predictors of long‐term all‐cause mortality. Results In this study of 4446 patients with AMI, 2223 patients with MASLD were matched with patients without MASLD using propensity scores. The mean follow‐up duration was 3.4 ± 2.4 years. The MASLD group had higher rates of obesity, diabetes and chronic kidney disease than their counterparts. Patients with MASLD had early excess all‐cause mortality (6.8% vs. 3.6%, p
endocrinology & metabolism
What problem does this paper attempt to address?